Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis
Open Access
- 27 January 2014
- journal article
- Published by Springer Science and Business Media LLC in BMC Pulmonary Medicine
- Vol. 14 (1), 5
- https://doi.org/10.1186/1471-2466-14-5
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective medical therapies. Recent research has focused on identifying the biological processes essential to the development and progression of fibrosis, and on the mediators driving these processes. Lysophosphatidic acid (LPA), a biologically active lysophospholipid, is one such mediator. LPA has been found to be elevated in bronchoalveolar lavage (BAL) fluid of IPF patients, and through interaction with its cell surface receptors, it has been shown to drive multiple biological processes implicated in the development of IPF. Accordingly, the first clinical trial of an LPA receptor antagonist in IPF has recently been initiated. In addition to being a therapeutic target, LPA also has potential to be a biomarker for IPF. There is increasing interest in exhaled breath condensate (EBC) analysis as a non-invasive method for biomarker detection in lung diseases, but to what extent LPA is present in EBC is not known. In this study, we used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to assess for the presence of LPA in the EBC and plasma from 11 IPF subjects and 11 controls. A total of 9 different LPA species were detectable in EBC. Of these, docosatetraenoyl (22:4) LPA was significantly elevated in the EBC of IPF subjects when compared to controls (9.18 pM vs. 0.34 pM; p = 0.001). A total of 13 different LPA species were detectable in the plasma, but in contrast to the EBC, there were no statistically significant differences in plasma LPA species between IPF subjects and controls. These results demonstrate that multiple LPA species are detectable in EBC, and that 22:4 LPA levels are elevated in the EBC of IPF patients. Further research is needed to determine the significance of this elevation of 22:4 LPA in IPF EBC, as well as its potential to serve as a biomarker for disease severity and/or progression.Keywords
This publication has 39 references indexed in Scilit:
- International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate LigandsPharmacological Reviews, 2013
- Exhaled Breath Condensates: Analyzing the Expiratory PlumeAmerican Journal of Respiratory and Critical Care Medicine, 2012
- The Lysophosphatidic Acid Receptor LPA1 Promotes Epithelial Cell Apoptosis after Lung InjuryAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of sclerodermaArthritis & Rheumatism, 2011
- Aiming drug discovery at lysophosphatidic acid targetsBritish Journal of Pharmacology, 2010
- A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelBritish Journal of Pharmacology, 2010
- Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulationProceedings of the National Academy of Sciences of the United States of America, 2010
- Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during DevelopmentMolecular and Cellular Biology, 2006
- The ins and outs of lysophosphatidic acid signalingBioEssays, 2004
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959